Anti-tumour necrosis factor alpha therapy in patients with impaired renal function.
作者信息
Hueber Axel J, Tunc Andac, Schett Georg, Manger Bernhard
出版信息
Ann Rheum Dis. 2007 Jul;66(7):981-2. doi: 10.1136/ard.2006.069211. Epub 2007 Mar 2.
Abstract
摘要
相似文献
1
Anti-tumour necrosis factor alpha therapy in patients with impaired renal function.肾功能受损患者的抗肿瘤坏死因子α治疗
Ann Rheum Dis. 2007 Jul;66(7):981-2. doi: 10.1136/ard.2006.069211. Epub 2007 Mar 2.
2
[Effectiveness and safety of the treatment with tumour necrosis factor alpha antagonists in rheumatoid arthritis patients].[肿瘤坏死因子α拮抗剂治疗类风湿关节炎患者的有效性和安全性]
Med Clin (Barc). 2005 Jun 4;125(1):35-6. doi: 10.1157/13076403.
3
Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.抗肿瘤坏死因子α疗法可调节重度类风湿关节炎患者的胃饥饿素。
Ann Rheum Dis. 2008 Nov;67(11):1644-6. doi: 10.1136/ard.2008.088773.
4
Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment.类风湿关节炎患者接受抗肿瘤坏死因子α治疗后，同时使用的糖皮质激素治疗量显著且持久减少。
Ann Rheum Dis. 2009 Dec;68(12):1934-6. doi: 10.1136/ard.2009.111807.
5
Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience.
Joint Bone Spine. 2013 Jul;80(4):438-40. doi: 10.1016/j.jbspin.2013.01.004. Epub 2013 Mar 1.
6
Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the 'VEDERA' trial.肿瘤坏死因子抑制剂治疗中度疾病活动度类风湿关节炎的疗效：“VEDERA”试验的亚组分析
Rheumatology (Oxford). 2022 Feb 2;61(2):868-869. doi: 10.1093/rheumatology/keab766.
7
Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.利妥昔单抗与抗肿瘤坏死因子-α阻滞剂联合治疗成功治愈严重难治性类风湿关节炎。
J Rheumatol. 2009 Sep;36(9):2125-6. doi: 10.3899/jrheum.090160.
8
Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor alpha agents.使用改善病情抗风湿药或抗肿瘤坏死因子α制剂治疗的类风湿关节炎完全缓解患者的磁共振成像
Ann Rheum Dis. 2007 Jan;66(1):134-5. doi: 10.1136/ard.2006.056432.
9
Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.B细胞清除疗法对肿瘤坏死因子α拮抗剂治疗无效的类风湿关节炎患者的疗效：一项开放标签观察性研究。
Ann Rheum Dis. 2006 Sep;65(9):1255-7. doi: 10.1136/ard.2005.051169. Epub 2006 Mar 15.
10
Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.肿瘤坏死因子-α拮抗剂治疗后临床缓解并不伴有类风湿关节炎患者不对称二甲基精氨酸的变化。
Clin Biochem. 2012 Nov;45(16-17):1399-403. doi: 10.1016/j.clinbiochem.2012.07.092. Epub 2012 Jul 20.
引用本文的文献
1
Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide.慢性肾脏病患者炎症性肠病药物的处方：实用指南。
Aliment Pharmacol Ther. 2025 Aug;62(4):400-418. doi: 10.1111/apt.70262. Epub 2025 Jul 2.
2
Real-World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney Disease.来自土耳其的真实世界见解：生物性改善病情抗风湿药在慢性肾脏病脊柱关节炎患者中的应用
Int J Rheum Dis. 2025 May;28(5):e70274. doi: 10.1111/1756-185X.70274.
3
Renal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics.肾脏疾病与治疗中的肾巨噬细胞和NLRP3炎性小体
Cell Death Discov. 2024 May 13;10(1):229. doi: 10.1038/s41420-024-01996-3.
4
Effect of tumor necrosis factor inhibitors on risk of cardiovascular disease in patients with axial spondyloarthritis.肿瘤坏死因子抑制剂对轴性脊柱关节炎患者心血管疾病风险的影响。
Arthritis Res Ther. 2022 Jun 13;24(1):141. doi: 10.1186/s13075-022-02836-4.
5
Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?慢性肾脏病强直性脊柱炎患者的抗TNF治疗：是否有效且安全？
Eur J Rheumatol. 2022 Apr;9(2):68-74. doi: 10.5152/eurjrheum.2022.21099.
6
Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice.银屑病关节炎：合并症对药物选择的影响。
Rheumatol Ther. 2022 Feb;9(1):49-71. doi: 10.1007/s40744-021-00397-7. Epub 2021 Nov 19.
7
Role of Macrophages and Related Cytokines in Kidney Disease.巨噬细胞及相关细胞因子在肾脏疾病中的作用。
Front Med (Lausanne). 2021 Jul 8;8:688060. doi: 10.3389/fmed.2021.688060. eCollection 2021.
8
Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits.银屑病患者的系统性银屑病治疗与合并症：潜在风险与益处综述
J Clin Aesthet Dermatol. 2019 Jun;12(6):46-54. Epub 2019 Jun 1.
9
Gender Is a Risk Factor for Annual Decline in Estimated Glomerular Filtration Rate in Patients Treated with Biological DMARDs in Rheumatoid Arthritis and Ankylosing Spondylitis: a Retrospective Observational Study.性别是接受生物 DMARDs 治疗的类风湿关节炎和强直性脊柱炎患者估计肾小球滤过率年度下降的风险因素：一项回顾性观察研究。
J Korean Med Sci. 2018 May 28;33(30):e188. doi: 10.3346/jkms.2018.33.e188. eCollection 2018 Jul 23.
10
Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease.抗肿瘤坏死因子α治疗类风湿关节炎和慢性肾脏病的效果
Rheumatol Int. 2015 Apr;35(4):727-34. doi: 10.1007/s00296-014-3146-4. Epub 2014 Oct 8.
本文引用的文献
1
Adverse reactions to biologic agents: focus on autoimmune disease therapies.生物制剂的不良反应：聚焦自身免疫性疾病治疗
J Allergy Clin Immunol. 2005 Oct;116(4):900-5. doi: 10.1016/j.jaci.2005.03.028.
2
Infliximab and nephrotic syndrome.英夫利昔单抗与肾病综合征。
Nephrol Dial Transplant. 2005 Dec;20(12):2824-6. doi: 10.1093/ndt/gfi180. Epub 2005 Oct 4.
3
Infliximab therapy in established rheumatoid arthritis: an observational study.英夫利昔单抗治疗已确诊的类风湿性关节炎：一项观察性研究。
Am J Med. 2005 May;118(5):515-20. doi: 10.1016/j.amjmed.2005.01.029.
4
Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.类风湿关节炎抗TNF-α治疗期间肾小球肾炎的发生
Nephrol Dial Transplant. 2005 Jul;20(7):1400-6. doi: 10.1093/ndt/gfh832. Epub 2005 Apr 19.
5
Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis.肿瘤坏死因子抑制剂：类风湿关节炎患者的风险与获益
Intern Med J. 2004 Dec;34(12):687-93. doi: 10.1111/j.1445-5994.2004.00710.x.
6
Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis.一名类风湿关节炎患者中，肾病综合征作为抗TNFα治疗的并发症。
Neth J Med. 2003 Apr;61(4):137-41.
7
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.15例继发于炎性关节炎的AA型淀粉样变性患者的抗肿瘤坏死因子α治疗：耐受性和疗效的随访报告
Arthritis Rheum. 2003 Jul;48(7):2019-24. doi: 10.1002/art.11163.
8
Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis.英夫利昔单抗治疗一名接受血液透析的类风湿关节炎患者。
J Rheumatol. 2002 Mar;29(3):636-7.
Zotero 插件